Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessi...
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: GlobeNewswire
ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024. Featured ScienceBempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes TrialFeatured Science: Vascular Outcomes in the SpotlightNovember 18, 2024, 8 - 9:15 a.m. CSTPresenter: Marc P. Bonaca, MD, MPH, FAHA, FACC Poster PresentationsLiver Steatosis and Liver Fibrosis Predict Major Adverse Cardiovascular Events in the CLEAR Outcomes TrialPoster PresentationCVD Science Smorgasbord IIZone 3, Science & Technology HallNovember 16, 2024, 10:30 - 11:30 a.m. CSTPresenter: Diederick (Rick) Grobbee, MD, PhD, FESC Statin Intolerance due to Muscle Symptoms Affects Management of Patients: Insights from the CLEAR Outcomes TrialModerat
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]Yahoo! Finance
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 11/20/24 - Form 4
- 11/19/24 - Form 144
- 11/14/24 - Form SC
- ESPR's page on the SEC website